ArticlePoultry science2026
Polysaccharide from Atractylodes macrocephala Koidz. protects against avian pathogenic Escherichia coli-induced intestinal barrier Dysfunction via Suppressing PI3K/Akt-Mediated Claudin-2 upregulation.
Article in Poultry science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Avian pathogenic Escherichia coli (APEC) is a leading cause of intestinal barrier dysfunction and diarrhea in chicks, resulting in substantial economic losses to the poultry industry. This study investigated the protective effects and underlying mechanism of polysaccharide from Atractylodes macrocephala Koidz. (PAMK) against APEC-induced intestinal injury using an integrated in vivo (chick) and in vitro (IPEC-J2 cell) approach. In vivo, PAMK intervention significantly reduced necropsy scores, alleviated growth retardation, and improved villus height-to-crypt depth ratios as well as brush border height. PAMK also attenuated the APEC-induced increase in goblet cell counts and upregulated MUC-2 mRNA expression, indicating enhanced chemical barrier function. Furthermore, PAMK suppressed the mRNA expression of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) and the pore-forming tight junction protein Claudin-2 in the jejunum. In IPEC-J2 cells, PAMK pretreatment inhibited APEC-induced upregulation of TNF-α and Claudin-2 at both mRNA and protein levels, effects that were phenocopied by the PI3K inhibitor LY294002. Mechanistically, PAMK suppressed APEC-induced phosphorylation of Akt and its downstream target GSK-3β, thereby blocking the PI3K/Akt/GSK-3β signaling cascade. Immunohistochemical analysis confirmed that APEC infection increased Claudin-2 protein abundance along the villus apical membrane. Collectively, these findings demonstrate that PAMK alleviates APEC-induced intestinal barrier dysfunction by inhibiting the PI3K/Akt/GSK-3β pathway to downregulate Claudin-2 expression, suggesting its potential as a dietary supplement to improve gut health in poultry production.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.